BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev 2021;40:819-35. [PMID: 34499267 DOI: 10.1007/s10555-021-09990-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Nishimoto A. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World J Gastroenterol 2022; 28(28): 3637-3643 [DOI: 10.3748/wjg.v28.i28.3637] [Reference Citation Analysis]
2 Song J, Kobayashi Y, Asano Y, Sato A, Taniguchi H, Ui-tei K. Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo. Cancers 2022;14:3162. [DOI: 10.3390/cancers14133162] [Reference Citation Analysis]
3 Nisar M, Paracha RZ, Adil S, Qureshi SN, Janjua HA. An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer. Front Oncol 2022;12:875188. [PMID: 35686109 DOI: 10.3389/fonc.2022.875188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yin C, Alqahtani A, Noel MS. The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. Cancers (Basel) 2022;14:2619. [PMID: 35681599 DOI: 10.3390/cancers14112619] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev 2022;187:114357. [PMID: 35605679 DOI: 10.1016/j.addr.2022.114357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang CX, Wang TT, Zhang KD, Li MY, Shen QC, Lu SY, Zhang J. Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma. Acta Pharmacol Sin 2022. [PMID: 35352018 DOI: 10.1038/s41401-022-00897-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shetu SA, Bandyopadhyay D. Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies. Int J Mol Sci 2022;23:3706. [PMID: 35409064 DOI: 10.3390/ijms23073706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Nauheim D, Moskal D, Renslo B, Chadwick M, Jiang W, Yeo CJ, Nevler A, Bowne W, Lavu H. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer. J Surg Oncol 2022. [PMID: 35333412 DOI: 10.1002/jso.26860] [Reference Citation Analysis]
9 Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou SI. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev 2021;101:102309. [PMID: 34715449 DOI: 10.1016/j.ctrv.2021.102309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]